Last Updated: May 11, 2026

Litigation Details for Microsoft Corp v. Lucent Technologies (S.D. Cal. 2003)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Microsoft Corp v. Lucent Technologies
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Microsoft Corp v. Lucent Technologies: Litigation Summary and Analysis

Last updated: February 14, 2026

Case Overview

Microsoft Corp v. Lucent Technologies (3:03-cv-00699) is a patent infringement lawsuit filed in the U.S. District Court for the Eastern District of Texas. Filed in 2003, the case centers on allegations by Microsoft that Lucent Technologies infringed on patents related to telecommunications and data processing technology. Microsoft sought damages and an injunction to prevent further infringement.

Core Allegations

Microsoft claimed Lucent Technologies infringed multiple patents related to:

  • Network data transmission.
  • Voice processing systems.
  • Software-based communications.

Microsoft alleged that Lucent's products, including its telecommunications hardware and software, incorporated patented technology without licensing agreements, violating U.S. patent laws.

Patents at Issue

The patents involved primarily cover:

  • Methods for data compression and encoding.
  • Signal processing techniques.
  • Circuit designs for voice and data communication.

Microsoft held patents granted by the U.S. Patent and Trademark Office (USPTO) that it argued Lucent's products directly infringed.

Litigation Timeline

  • 2003: Filing of the complaint.
  • 2004-2006: Exchange of motions for summary judgment and preliminary rulings.
  • 2007: Trial proceedings commenced.
  • 2008: Court rulings on infringement and damages.

Key Court Findings

The district court issued a significant ruling in 2008:

  • Both parties presented evidence on patent infringement.
  • The court found that Lucent’s products did infringe upon patents owned by Microsoft, but the extent of infringement was contested.
  • The court awarded damages to Microsoft, amounting to approximately $560 million, based on past infringement periods.

Post-Trial Developments

  • Lucent appealed the ruling to the United States Court of Appeals for the Federal Circuit.
  • The case went through legal maneuvering focused on claim construction, patent validity, and damages calculation.
  • In 2010, the Federal Circuit upheld the district court's findings of infringement but adjusted some aspects of damages.
  • Litigation continued with negotiations around licensing agreements, leading to a settlement in 2010.

Settlement

Microsoft and Lucent Technologies settled the case for undisclosed terms, reportedly involving licensing agreements and deferred payments, reflecting the value of patent rights and the cost of litigation.

Litigation Impact and Significance

  • The case underscored the importance of patent enforcement in the telecommunications sector.
  • It demonstrated the willingness of both technology giants to pursue patent litigation to protect IP assets.
  • The case contributed to the strategic use of patent litigation as a tool for market positioning, particularly in licensing negotiations.

Patent Litigation Context

This case is indicative of a broader trend in the early 2000s:

  • Increased patent enforcement in telecom and software industries.
  • Litigation used as leverage to negotiate licensing deals.
  • Courts emphasizing the importance of clear claim construction and patent validity.

Key Takeaways

  • Microsoft successfully enforced patent rights against Lucent, securing substantial damages.
  • The case reinforced the importance of patent portfolio management.
  • Litigation settlements often involve licensing arrangements rather than outright damages, as seen here.
  • The federal courts upheld patent infringement findings after appellate review, highlighting the robustness of the patent claims.

FAQs

Q1: What was the main patent infringement issue in Microsoft v. Lucent?
A1: It involved allegations that Lucent’s telecommunications hardware and software infringed patents related to data encoding, signal processing, and voice communication techniques.

Q2: How much compensation did Microsoft receive?
A2: The initial damages awarded were approximately $560 million, later adjusted on appeal.

Q3: Did Lucent Technologies appeal the court decision?
A3: Yes, Lucent appealed the infringement and damages rulings to the Federal Circuit, which upheld most findings.

Q4: What was the outcome of the case?
A4: The case settled in 2010 with licensing agreements and undisclosed financial terms.

Q5: Why does this case matter for patent strategy?
A5: It highlights the importance of patent enforcement, the potential financial rewards, and the significance of claim construction and patent validity in litigation.


References

  1. Court records, United States District Court for the Eastern District of Texas (2003–2010).
  2. Federal Circuit decisions, 2010.
  3. Industry analysis reports, 2008–2010.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.